Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues
- 19 February 2008
- journal article
- Published by SAGE Publications in Statistical Methods in Medical Research
- Vol. 17 (5), 515-518
- https://doi.org/10.1177/0962280207081862
Abstract
There has been interest in using progression-free survival as a surrogate endpoint for overall survival in oncology clinical trials. In order to objectively define this endpoint, clear understanding of what progression means, how it is measured and what its implications are need to be discussed. This article discusses some regulatory aspects of using progression-free survival as an endpoint.Keywords
This publication has 3 references indexed in Scilit:
- Sorafenib for the Treatment of Advanced Renal Cell CarcinomaClinical Cancer Research, 2006
- Accelerated Approval of Oncology Products: A Decade of ExperienceJNCI Journal of the National Cancer Institute, 2004
- End Points and United States Food and Drug Administration Approval of Oncology DrugsJournal of Clinical Oncology, 2003